In Brief: GSK Sales Drop; FTC Bans Firm From U.S. Market; FDA Warning Letters
This article was originally published in The Tan Sheet
Executive Summary
GSK consumer sales drop 4%; Canadian firm banned from weight loss market; basic labeling failures triggers FDA warning letter; claims make Puna Noni products drugs; FDA finds another tainted supplement; and study shows Herbalife is not pyramid scheme.
You may also be interested in...
Industry Suggests Increase In Spiked Supplements Reflects FDA Investment In Testing, Targeted Selection
The number of products marketed as supplements and identified as tainted in 2013 grew 136% from 2011 – the year after FDA announced it would take “swift and strong” enforcement action. Trends in recalls and public notifications likely reflect FDA’s investment in testing products, a strategy in need of updating, supplement industry trade groups say.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.